Press release
Unfractionated Heparin Market Size, Share, Industry, Forecast and outlook (2024-2031)
DataM Intelligence
Global Unfractionated Heparin Market Predicted to Soar with High CAGR by 2031
The global unfractionated heparin market is poised to witness significant growth during the forecast period of 2024-2031, projecting a high Compound Annual Growth Rate (CAGR). Heparin, a natural agent utilized for preventing clot formation in vessels, encompasses two widely used types: unfractionated heparin (UFH) and low molecular weight heparin (LMWH).
UFH, a fast-acting blood thinner, collaborates with antithrombin, a natural protein, to impede clot formation. The market's expansion is attributed to the escalating incidence of coagulation disorders and a substantial rise in individuals afflicted by chronic diseases.
To know more Insights Download Sample : https://www.datamintelligence.com/download-sample/unfractionated-heparin-market
Market Dynamics Driving Growth
The global unfractionated heparin market is propelled by the escalating prevalence of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism. Additionally, health organizations are intensifying their awareness initiatives, potentially augmenting the market in the forthcoming years. Numerous biopharmaceutical firms are pioneering innovative medications to enhance heparin's therapeutic efficacy and mitigate its side effects.
The burgeoning prevalence of thromboembolic disorders and heightened awareness regarding unfractionated heparin usage, coupled with its ease of use and cost-effectiveness, are slated to fuel market growth. According to data from the Centers for Disease Control and Prevention (CDC), approximately 900,000 individuals in the U.S. are affected annually by deep venous thromboembolism and Pulmonary Embolism (DVT/PE). UFH's utilization significantly reduces the incidence of DVTs in non‐surgical patients, as evidenced by a review encompassing 16 trials and 34,369 individuals.
Low cost and immediate action are anticipated to drive market expansion. UFH is preferred for patients at high risk of bleeding complications due to its rapid activity and reversibility. Its mechanism involves binding to antithrombin, enhancing its ability to inhibit crucial clotting factors within minutes. UFH's clinical utility extends beyond anticoagulation, with burgeoning interest in its potential applications spanning from anti-inflammatory to anti-tumor functions, and as a carrier for drug delivery systems.
Challenges Hindering Market Growth
Despite its clinical efficacy, UFH usage is marred by adverse effects, notably Heparin-induced thrombocytopenia (HIT), characterized by an inconsistent increase in clotting, leading to complications. UFH and LMWH therapies are associated with a high incidence of drug-related problems and side effects, including thrombocytopenia, bleeding events, and osteopenia, amplifying the overall cost of care.
COVID-19 Impact Analysis
The COVID-19 pandemic has presented both positive and negative ramifications on the unfractionated heparin market. With COVID-19 associated with respiratory diseases, the demand for heparin surged, given its role in subduing respiratory inflammation and mitigating clotting risks associated with the infection. The rising incidence of thromboembolic diseases amidst the pandemic underscores the pivotal role of heparin in managing COVID-19 complications, fostering market growth.
Market Segment Analysis
By source, the market is segmented into bovine and porcine, with the porcine segment dominating due to regulatory restrictions on bovine-derived heparin post-1990s. The market is further segmented based on applications, including deep venous thromboembolism, arterial fibrillation, renal impairment, and coronary artery disease. Among these, coronary artery disease exhibits the highest prevalence, reflecting the increasing burden of cardiovascular diseases globally.
Geographical Insights
North America commands a leading position in the global unfractionated heparin market, driven by the rising prevalence of thromboembolic disorders. The market is witnessing growth trajectories in the Asia Pacific region, propelled by increasing adoption of heparin for managing thromboembolic complications.
Competitive Landscape
The global unfractionated heparin market is characterized by the presence of both international and local players, with significant investments in research and development to enhance therapeutic efficacy and mitigate side effects. Key players include B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens AG, and Sagent Pharmaceuticals.
Related Report:
specialty generics market https://www.datamintelligence.com/research-report/specialty-generics-market
metastatic prostate cancer treatment market https://www.datamintelligence.com/research-report/metastatic-prostate-cancer-treatment-market
smoking cessation aids market https://www.datamintelligence.com/research-report/smoking-cessation-aids-market
optical disorders drugs market https://www.datamintelligence.com/research-report/optical-disorders-drugs-market
biological multiplex assays market https://www.datamintelligence.com/research-report/biological-multiplex-assays-market
Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Unfractionated Heparin Market Size, Share, Industry, Forecast and outlook (2024-2031) here
News-ID: 3399229 • Views: …
More Releases from DataM Intelligence 4Market Research
Saudi Arabia Laboratories Market Poised for Strong Growth Amid Rising Healthcare …
Market Size and Growth:
Saudi Arabia Laboratories Market size was valued at US$ 766.4 million in 2021 and is estimated to reach US$ million by 2029, growing at a CAGR of 7.3 % during the forecast period (2024-2031).
Saudi Arabia Laboratories Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make…
Interventional Cardiology and Peripheral Vascular Devices Market Set for Robust …
Market Size and Growth:
The Global Interventional Cardiology and Peripheral Vascular Devices Market reached US$ 20.11 billion in 2023, with a rise to US$ 21.58 billion in 2024, and is expected to reach US$ 41.17 billion by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.
Interventional Cardiology and Peripheral Vascular Devices Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities,…
Cardiac Monitoring Devices Market Surges with Rising Heart Disease Cases & AI-Dr …
Market Size and Growth:
The Cardiac Monitoring Devices Market size was valued at USD 7,696.50 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 5.90% over the forecast period 2024-2031.
Cardiac Monitoring Devices Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions…
Global Dental Crowns and Bridges Market Poised for Robust Growth Driven by Risin …
Market Size and Growth:
The Dental Crowns and Bridges Market size was valued at USD 3,840.30 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 7.30% over the forecast period 2024-2031.
Dental Crowns and Bridges Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make…
More Releases for UFH
Unlocking the potential of the underfloor heating market, the role of heating sy …
The underfloor heating (UFH) industry has witnessed significant growth over the past decade, driven by increasing consumer demand for energy-efficient, comfortable, and space-saving heating solutions. UFH systems, which can be broadly categorized into hydronic (water-based) and electric (dry) systems, have gained popularity for their ability to provide even, gentle heat throughout a room, eliminating the need for bulky radiators or space-consuming heating equipment. These systems work by distributing heat across…
Underfloor Heating Market Size, Share, Trends, and Analysis: 2024-2030
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2024 latest report "Underfloor Heating- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030". Based on current situation and impact historical analysis (2019-2023) and forecast calculations (2024-2030), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.
Underfloor heating (UFH) is a…
Global Heparin Market to Reach USD 5.58 Billion in 2022, Expected to Grow at 5.5 …
Government support for healthcare and growing R&D activities are key drivers of market growth
The global heparin market, valued at USD 5.58 billion in 2022, is set to experience steady growth with a projected compound annual growth rate (CAGR) of 5.5% during the forecast period. This growth is driven by increasing government investments in healthcare infrastructure and rising research and development efforts to enhance the therapeutic potential of heparin while minimizing…
Unfractionated Heparin Market is Projected to Grow at a CAGR of 6.4% by 2027 | T …
Unfractionated heparin (UFH) is a naturally occurring anticoagulant that acts by potentiating the activity of antithrombin III, thereby inhibiting the coagulation cascade and preventing the formation of blood clots. UFH is derived from porcine or bovine sources and is characterized by its heterogeneous mixture of polysaccharide chains of varying lengths. Unlike low molecular weight heparins (LMWHs), which are derived from UFH and have a more predictable anticoagulant effect, UFH exhibits…
Rising from the Floor: Exploring the Global Underfloor Heating Renaissance
Introduction:
In 2021, the global underfloor heating market warmed up to a valuation of US$ 4.6 billion, with projections indicating a robust ascent to reach US$ 8.41 billion by 2030. Fueled by advancements in radiant heat technology, underfloor heating (UFH) is emerging as a cleaner, more energy-efficient alternative, redefining how we experience warmth within our living spaces.
Understanding Underfloor Heating:
Underfloor heating represents a transformative approach to individual dwelling comfort, leveraging radiant heat…
Unfractionated Heparin Market New Trends, Market Segmentation, Footprint With Th …
Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a natural protein in the body, to block clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to…
